Artículo
Influence of capsule size on the in vitro activity of antifungal agents against clinical Cryptococcus neoformans var. grubii strains
Fecha de publicación:
03/2012
Editorial:
Society for General Microbiology
Revista:
Journal of Medical Microbiology
ISSN:
0022-2615
Idioma:
Inglés
Tipo de recurso:
Artículo publicado
Clasificación temática:
Resumen
Cryptococcosis causes disseminated disease in AIDS patients. In contrast to what occurs in laboratory conditions, a large capsule is produced by Cryptococcus neoformans in vivo during infection. The aim of this study was to compare the in vitro activity of different antifungal agents against 34 clinical isolates of C. neoformans var. grubii without or with capsule induction (CLSI, CLSI-C, respectively), following the CLSI M27A3 document. Capsule induction was obtained by addition of NaHCO 3 and incubation with CO 2. The geometric means of the MICs, in μg ml -1, for CLSI and CLSI-C cultures, respectively, were 1.9 and 9.8 for fluconazole; 0.04 and 0.08 for itraconazole; 0.04 and 0.05 for voriconazole; 0.16 and 0.38 for amphotericin B; and 1.6 and 5.6 for 5-flucytosine. Thus fluconazole showed the highest MICs after capsule induction. Determination of antifungal activity after capsule induction may be clinically relevant and could be used to evaluate the correlation between in vitro results and clinical outcome.
Palabras clave:
CAPSULE
,
CRYPTOCOCCUS
,
ANTIFUNGAL AGENTS
,
FUNGAL SUSCEPTIBILITY
Archivos asociados
Licencia
Identificadores
Colecciones
Articulos(SEDE CENTRAL)
Articulos de SEDE CENTRAL
Articulos de SEDE CENTRAL
Citación
Vitale, Roxana Gabriela; Pascuccelli, Veronica; Afeltra, Javier; Influence of capsule size on the in vitro activity of antifungal agents against clinical Cryptococcus neoformans var. grubii strains; Society for General Microbiology; Journal of Medical Microbiology; 61; 3; 3-2012; 384-388
Compartir
Altmétricas